Novartis Backs 2022 View – MarketWatch
admin Corrections & Amplifications This headline was corrected at 0533 GMT to reflect it should be…
Read MoreNovartis
Novartis hemoglobinuria trial meets two primary endpoints
Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to…
Read MoreNovartis to spin off, list Sandoz business
Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as…
Read MoreNovartis sales and profit drop, but backs 2022 guidance
Corrections & Amplifications This headline was corrected at 0516 GMT becuase the core oper income…
Read MoreDow Jones Newswires: Novartis sales and profit drop, but backs 2022 guidance
The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from $2.89…
Read More